Mielóma multiplex: vizsgálatok itt: Kína
204 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleStudy to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
- Where
- Wuhan
- Életkor
- 18 év to 70 év
- People
- 54
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT06140966 - No phaseTaking peopleScreening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
- Where
- Guangzhou
- People
- 200
- Run by
- Zhujiang Hospital
See details and how to joinNCT05686447 - 1/2. fázisTaking peopleThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 90
- Run by
- Tianjin Medical University General Hospital
See details and how to joinNCT06911710 - 1/2. fázisTaking peoplePurinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 144
- Run by
- Chengdu Zenitar Biomedical Technology Co., Ltd
See details and how to joinNCT06484829 - 3. fázisNot yet taking people in KínaA Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 386
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06895512 - 2/3. fázisTaking peopleKPD Consolidation After ASCT in NDMM Patients
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 202
- Run by
- Peking University People's Hospital
See details and how to joinNCT06879379 - 1/2. fázisTaking peopleBCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
- Where
- Kunming
- Életkor
- 18 év to 75 év
- People
- 80
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT04271644 - 1/2. fázisTaking peoplea Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
- Where
- Kunming
- Életkor
- 18 év to 75 év
- People
- 80
- Run by
- Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT04776330 - 2. fázisTaking peopleAll-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
- Where
- Xiamen
- Életkor
- 18 év and over
- People
- 25
- Run by
- The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06158412 - Korai 1. fázisTaking peopleA Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
- Where
- Wuhan
- Életkor
- 18 év and over
- People
- 24
- Run by
- Chunrui Li
See details and how to joinNCT06791681 - 1/2. fázisNot yet taking people in KínaA Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
- Where
- Wuhan, Xianning, Zhengzhou
- Életkor
- 18 év to 65 év
- People
- 42
- Run by
- Fuling Zhou
See details and how to joinNCT06799676 - No phaseTaking peopleA Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
- Where
- Taiyuan
- People
- 45
- Run by
- Shanxi Bethune Hospital
See details and how to joinNCT06783816 - 1. fázisTaking peopleSafety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- The Third Affiliated Hospital of Southern Medical University
See details and how to joinNCT06758713 - 1/2. fázisTaking peopleSafety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Where
- Xuzhou
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Xuzhou Medical University
See details and how to joinNCT06759181 - No phaseTaking peopleCharacteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
- Where
- Guanzhou
- Életkor
- 45 év and over
- People
- 2990
- Run by
- Zhujiang Hospital
See details and how to joinNCT06690593 - 1/2. fázisTaking peopleA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Where
- Beijing, Nanchang, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xian, Xuzhou
- Életkor
- 18 év and over
- People
- 116 worldwide
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT06083207 - Korai 1. fázisTaking peopleA Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT06732232 - Korai 1. fázisTaking peoplea Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 24
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT06718270 - 1. fázisTaking peopleA Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
- Where
- Chengdu, Shanghai
- Életkor
- 18 év to 75 év
- People
- 136
- Run by
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06700395 - No phaseTaking peopleRisk Stratification and MRD-driven Maintenance for MM After ASCT
- Where
- Beijing, Harbin
- Életkor
- 18 év and over
- People
- 100
- Run by
- Peking University People's Hospital
See details and how to joinNCT06697483 - No phaseTaking peopleConversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- Where
- Suzhou
- Életkor
- 18 év and over
- People
- 50
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06682156 - 1. fázisTaking peopleA Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Beijing, Hangzhou, Xi’an
- Életkor
- 18 év to 75 év
- People
- 58
- Run by
- Zhejiang University
See details and how to joinNCT06644118 - 1/2. fázisTaking peopleA Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 48
- Run by
- Keymed Biosciences Co.Ltd
See details and how to joinNCT05299424 - 2. fázisTaking peopleChimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
- Where
- Xiamen
- Életkor
- 18 év to 80 év
- People
- 5
- Run by
- The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06581640 - No phaseTaking peopleIntestinal Flora and Immunity in Monoclonal Gammopathy Patients
- Where
- Guanzhou
- Életkor
- 45 év and over
- People
- 300
- Run by
- Zhujiang Hospital
See details and how to joinNCT06539832